Programme
Day 1 - 20 November, 2015 (Friday)
Regency Ballroom I&II, Hyatt Regency Hong Kong, Tsimshatsui, Hong Kong |
|
| Time | Topics & Speakers |
| 13:00 – 14:00 | Registration |
| Session I: Pre-clinical Oncology Research Chair: Professor Yu-lung Lau, Chief Director, Clinical Trials Centre, The University of Hong Kong, Hong Kong, China
Chair: Dr. Tommy Cheung, Deputy Medical Director (Clinical Pharmacology), Phase 1 Clinical Trials Centre, The University of Hong Kong, Hong Kong, China |
|
14:00 – 14:30 |
The Development of BrachySil® – from Bench to First-in-Man  Professor Pierce Chow, Senior Consultant Surgeon, National Cancer Center Singapore and Singapore General Hospital, Singapore |
| 14:30 – 15:00 | Role and Regulation of the Forkhead Transcription Factor FOXM1 in Breast Cancer and Drug Resistance Professor Eric Lam, Professor of Molecular Oncology, Department of Surgery and Cancer, Imperial College London, London, United Kingdom |
| 15:00 - 15:30 | Haemoglobin-based Oxygen Carrier for Cancer Treatment Dr. Gilberto Leung, Clinical Associate Professor, Department of Surgery, The University of Hong Kong, Hong Kong, China |
| 15:30 – 16:00 | Coffee Break |
| 16:00 – 16:30 | Opening Ceremony Welcome address by Dr. Che-chung Luk, Cluster Chief Executive, Hong Kong West Cluster, Hospital Authority, Hong Kong, China Opening Remarks by Officiating Guest – Dr. Wing-man Ko, BBS, JP, Secretary for Food and Health of Hong Kong SAR Government, Hong Kong, China |
| Dr. Cheng Yu Tung Award Lecture in Drug Development Chair: Professor Karen Lam, Chairman, Committee of Management, Clinical Trials Centre, The University of Hong Kong, Hong Kong, China
Chair: Dr. Thomas Yau, Clinical Assistant Professor Department of Medicine, The University of Hong Kong, Hong Kong, China
| |
| 16:30 - 17:15 | Challenges and Opportunities of Early Drug Development in the Era of Personalized Medicine Professor S. Gail Eckhardt, Professor of Medicine/Oncology, Stapp Harlow Chair in Cancer Research, University of Colorado School of Medicine / Associate Director of Translational Research, University of Colorado Cancer Center, Aurora, United States |
| Plenary Section I Chair: Professor Anne Lee, Clinical Professor and Head, The University of Hong Kong, Hong Kong, China
Chair: Professor Ching-wan Lam, Director of Drug Metabolism and Pharmacokinetics, Phase 1 Clinical Trials Centre, Department of Clinical Oncology, The University of Hong Kong, Hong Kong, China |
|
| 17:15 - 17:45 | Cancer Evolution: Implications for Early Phase Drug Development Professor Charles Swanton, Senior Group Leader, The Francis Crick Institute / Professor of Cancer Medicine, University College London Hospitals and Cancer Institute, London, United Kingdom |
| 17:45 - 18:15 | Research Integrity and the Need for a Culture Change in Academic Medicine Professor Lee M. Ellis, Professor of Surgery, and Molecular & Cellular Oncology, The William C. Liedtke, Jr. Chair in Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States |
| 18:15 - 18:45 | Future Oncology Targets: Immunotherapy, Metabolism and Aneuploidy Professor Tak-wah Mak, Director, The Campbell Family for Breast Cancer Research at Princess Margaret Cancer Centre, University Health Network / University Professor, Department of Medicine, Medical Biophysics and Immunology, University of Toronto, Toronto, Canada |
Day 2 - 21 November, 2015 (Saturday)
Regency Ballroom I&II, Hyatt Regency Hong Kong, Tsimshatsui, Hong Kong |
|
| Time | Topics & Speakers |
| 08:30 - 09:00 | Registration |
| Session II: Early Clinical Research on Asian Diseases Chair: Professor Ching-lung Lai, Chair Professor, Department of Medicine, The University of Hong Kong, Hong Kong, China Chair: Professor Thomas Leung, Director of Lo Ka Chung Centre for Natural Anti-Cancer Drug Development, The Hong Kong Polytechnic University, Hong Kong, China |
|
| 09:00 - 09:30 | Diabetes and Heart Failure: Addressing an Unmet Need through ‘Proof of Concept’ Trials Professor Chim C Lang, Professor of Cardiology, Medical Research Institute, Ninewells Hospital and Medical School, Dundee, United Kingdom |
| 09:30 - 10:00 | New Drug Research for Chronic Hepatitis B Professor Man-fung Yuen, Chair Professor of Gastroenterology and Hepatology, Department of Medicine, The University of Hong Kong, Hong Kong, China |
| 10:00 - 10:30 | Coffee Break |
| Plenary Section II Chair: Professor Chor-sang Chim, S H Ho Professorship in Haematology and Oncology, Department of Medicine, The University of Hong Kong, Hong Kong, China
Chair: Dr. Joanne Chiu, Deputy Medical Director, Oncology, Phase 1 Clinical Trials Center, The University of Hong Kong, Hong Kong, China |
|
| 10:30 - 11:00 | Intrahepatic Cholangiocarcinoma; Novel Genetic Signatures and Therapeutic Targets Dr. Andrew Zhu, Director of Liver Cancer Research, Massachusetts General Hospital Cancer Center, Boston, United States |
| 11:00 - 11:30 | The Travel with Daratumumab: From a Phase 1 First-in-Man Trial to the Market Professor Torben Plesner, Professor of Haematology, University of Southern Denmark, Vejle, Denmark |
| 11:30 - 12:00 | Promising Agents in Gastric Cancer Clinical Trials Dr. Stephen Leong, Associate Professor, Division of Medical Oncology, Department of Medicine, University of Colorado, Aurora, United States |
| 12:00 - 13:00 | Lunch |
| Session III: Early Clinical Development in Asia Chair: Dr. David Yang, Chief Executive Officer, MicroConstants China Inc., Beijing, China Chair: Ms. Cathy Lee, Director, Clinical Operations and Taiwan Site Head, INC Research Taiwan, Taipei, Taiwan |
|
| 13:00 - 13:25 | Phase 1 Clinical Trials in Taiwan Dr. Wing-kai Chan, Advisor, The Center of Excellence for Clinical Trial and Research, National Taiwan University Hospital, Taipei, Taiwan |
| 13:25 - 13:50 | Ethics and Scientific Oversight for Phase 1 Clinical Trials in Hong Kong Professor Sydney Tang, Clinical Professor, Department of Medicine, The University of Hong Kong, Hong Kong, China |
| 13:50 - 14:15 | Translational and Early Phase Clinical Research in Singapore Dr. Danny Soon, Medical Director, D3 (Drug Discovery and Development), Agency for Science, Technology and Research (A*STAR), Singapore |
| 14:15 - 14:40 | Recent CFDA Policy Changes & Future New Drug Development in China Panelists: Prof. Haiyan LI, Beijing University No.3 Hospital Dr. Jian PENG, SVP, Shenogen Inc Prof. Ping Sheng XU, Xiangya Hospital Prof. Xing ZENG, Guangzhou TCM Hospital |
| 14:40 - 15:00 | Coffee Break |
| Session IV: Drug Development in the Pharmaceutical Industry Chair: Dr. Jason Wu, Executive Vice President & Chief Medical Officer, WuXiPRA Clinical Research (Shanghai) Co. Ltd., Shanghai, China Chair: Mr. Wayland Hui, Director, Clinical Operations, Department of Site Management, Quintiles Hong Kong, Hong Kong, China |
|
| 15:00 - 15:20 | Orchestrates Novartis Early Pipelines Dr. Jonathan Sun, Regional Medical Director, Medical Affairs, Novartis Oncology, Shanghai, China |
| 15:20 - 15:40 | Immuno-Oncology, The New Era of Cancer Treatment Dr. Ted Lee, Disease Area Head, Immuno-Oncology, Pacific Rim, Department of Medical, R&D, Bristol-Myers Squibb Company, Seoul, Korea |
| 15:40 - 16:00 | From Precise Diagnosis to More Personalized Therapy Dr. Qin-yong Dai, Medical Director, Department of Medical, Roche Hong Kong, Hong Kong, China |
| 16:00 - 16:15 | Summary and Closing Remarks Professor Bernard Cheung, Medical Director, Phase 1 Clinical Trials Centre, The University of Hong Kong, Hong Kong, China |
As of 20th Nov, 2015